SNY Sanofi

By Colin Kellaher

Sanofi S.A. (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN) on Tuesday said the European Commission approved expanded use of Dupixent for adults with chronic rhinosinusitis with nasal polyposis, or CRSwNP.

The companies said Dupixent is now indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery don't provide adequate disease control.

Sanofi and Regeneron said Dupixent is the first biologic approved in the European Union for adults with severe CRSwNP, a disease of the upper airway that obstructs the sinuses and nasal passages.

Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 29, 2019 08:57 ET (12:57 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.